Conditions are ripe for reverse mergers
Redx makes the most of Jounce’s demise, but is the poor reputation of reverse mergers warranted?
No Blys for Vera
Atacicept hits in phase 2, but uncompetitive data are seen as good news for its IgAN rivals.
The Sting is dead; long live the Sting
Yesterday’s deal between GSK and Mersana threw the spotlight back on a forgotten oncology mechanism.
Significant readouts for small players
Praxis and Relmada target depression as Athira and Taurx tackle Alzheimer’s.
Key data reveals for the small players
Praxis, Proqr and Nordic Nanovector are awaiting important data.
Vertex finally catches a break
The group gets a long-awaited win in kidney disease, but sales potential is hard to call.